The safety and efficacy of the Chinese communist virus vaccine produced in China have been questioned by the outside world. Zhong Nanshan, a Chinese Communist Party epidemic prevention expert, recently spoke bluntly about Chinese vaccines, saying that even after planting a vaccine, one must take precautions; he said, “Will you get infected after vaccination? No one knows.
In an interview with CCTV reporters on December 30, Zhong Nanshan said, “It’s not right to put all your hopes on vaccines.” He stressed that even after vaccination, prevention is needed when going to high prevalence areas, and the two aspects should be combined.
Zhong Nanshan also said bluntly that after the vaccine, “no one knows whether the antibody will be infected and whether there are symptoms of infection. The infection has no symptoms, but no one knows if it will be transmitted to people.
On Dec. 30, officials from the Communist Party’s health and Welfare Commission confessed that the local epidemic is spreading, multi-point spreading and even localized outbreaks, and that “this will become the norm. In other words, the epidemic is out of control in China.
Communist authorities plan to vaccinate 50 million Chinese people before the Chinese New Year holiday. The South China Morning Post reported on Dec. 17 that inactivated vaccines made by Sinopharm and Beijing-based Sinovac Holdings Biotechnology Co.
Authorities require that the vaccine be administered by the end of the Chinese New Year holiday. The first phase of 50 million doses of the vaccine is required to be administered by Jan. 15 next year; the second phase is to be completed by Feb. 5.
There are widespread concerns about the safety and effectiveness of the Chinese-made vaccine. In a December 16 article in the Financial Times, it was pointed out that none of the vaccines made in China had completed the research and development process, and that administering them to the public now would be a safety concern, raising questions about the potential for problems with the Chinese vaccine.
Many Chinese people who know the inside story are also afraid to receive Chinese vaccines. Ms. Chen in Wuhan revealed that an insider told her not to play and to wait a little longer. “They still don’t have a long time for clinical trials, so they (doctors) told me not to fight first.”
Shanghai officials recently mapped hospital staff and the percentage of health care workers who refused vaccination exceeded 90 percent.
Zhang Wenhong, director of the infection department at Huashan Hospital affiliated with Fudan University in Shanghai, publicly said at an annual event for physicians on Dec. 20 that “the vaccine should be given to leaders first,” sparking hot debate on the Internet.
Some netizens quipped, “Vaccines must be given to high-risk groups first, and the general public can take a bit later.”
Some netizens also said bluntly, “Not to fight if it is not mandatory, the unknown is the scariest.” “Wait for it, wait for a mature and safe vaccine without side effects to hit the market.”
On Dec. 30, China Bio Beijing said that a new crown vaccine developed by China National Pharmaceutical Group (Sinopharm) had an efficiency rate of 79 percent, according to data analyzed during the phase 3 clinical trial.
In comparison, the final data from the Phase 3 clinical trial of the U.S. Pfizer vaccine showed that its vaccine was 95% effective. And the Phase 3 trial results of Modena Pharmaceuticals’ vaccine showed an efficiency rate of 94.1%.
China National Pharmaceutical Group said the data results met the minimum standards required by Communist Party regulators and that it had submitted a marketing application.
The Chinese vaccine was approved this month in Bahrain and the United Arab Emirates, according to RFE/RL. The two Gulf states each previously said the vaccine was 86 percent effective.
Neither Sinopharm nor the regulators in Bahrain and the UAE have released details of the analysis, and it is unclear why they reported differences in the vaccine’s effectiveness, the report said.
The UAE government has reportedly begun providing the Chinese vaccine to 1 million of its own residents, as well as 8 million foreign residents. But international experts question whether the Chinese vaccine meets the best global standards.
Recent Comments